• 1. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 2. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 3. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 4. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 5. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Sesquiterpenoids Artemisinins
• Sesquiterpenoids
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances

Artemether (CAS No.71963-77-4): A Comprehensive Overview of Its Pharmacological Properties and Therapeutic Applications

Artemether, a derivative of artemisinin, is a semi-synthetic antimalarial agent with a unique chemical structure that has garnered significant attention in the field of antiparasitic drug development. As a 1,2-benzenediol derivative, its molecular formula C₁₅H₂₄O₅ and molecular weight of 284.35 g/mol reflect its complex pharmacophore, which plays a critical role in its antimalarial activity and antiprotozoal mechanisms. The compound is widely recognized for its efficacy against Plasmodium falciparum and Plasmodium vivax, two major species responsible for malaria transmission. Recent studies have further expanded its therapeutic potential to include leishmaniasis, trypanosomiasis, and schistosomiasis, highlighting its broad-spectrum antiparasitic properties.

Artemether is synthesized through a series of chemical modifications of artemisinin, a natural product derived from Artemisia annua. This process enhances its solubility, stability, and bioavailability, making it a preferred choice for oral administration. The compound's 1,2-benzenediol core structure is crucial for its interaction with heme and iron in the parasite's environment, leading to the formation of reactive oxygen species (ROS) that disrupt cellular processes. This mechanism is distinct from traditional antimalarials such as chloroquine and quinine, which target different pathways in the parasite's life cycle.

Recent research has focused on the mechanism of action of Artemether, particularly its role in mitochondrial dysfunction in parasitic organisms. A 2023 study published in Frontiers in Microbiology demonstrated that Artemether induces mitochondrial membrane permeabilization and oxidative stress in Leishmania donovani, leading to apoptosis in the parasite. This finding underscores the compound's potential as a targeted antiparasitic agent with minimal impact on host cells. Additionally, the compound's lipophilicity allows it to penetrate the parasitic cell membrane effectively, enhancing its therapeutic efficacy.

The clinical application of Artemether has been extensively explored, particularly in the treatment of malaria and leishmaniasis. In a 2022 meta-analysis published in The Lancet Infectious Diseases, Artemether was found to be highly effective in reducing parasitemia and improving survival rates in patients with severe malaria. The compound's rapid onset of action and low toxicity profile make it a preferred choice for acute malaria treatment. Furthermore, its combination with lumefantrine in the form of Artemether-Lumefantrine (AL) has been endorsed by the World Health Organization (WHO) for malaria prophylaxis in endemic regions.

Recent advancements in nanoformulation technology have further improved the pharmacokinetic properties of Artemether. A 2024 study in Nature Nanotechnology reported the development of liposomal Artemether nanoparticles, which significantly enhance the compound's bioavailability and targeted delivery to parasitic tissues. This innovation addresses the limitations of conventional formulations, which often suffer from poor solubility and inconsistent absorption rates. The nanoformulation also reduces the risk of drug resistance by maintaining a sustained release of the active compound in the bloodstream.

The pharmacodynamics of Artemether are closely linked to its metabolic pathways and drug interactions. Research published in Drug Metabolism and Disposition in 2023 revealed that Artemether is primarily metabolized in the liver via cytochrome P450 enzymes, with metabolites such as artemether lactone and artemisinic acid being the main byproducts. These metabolites contribute to the compound's prolonged half-life and enhanced therapeutic effect. However, the potential for drug-drug interactions with other medications, such as anticonvulsants and antiretrovirals, remains a concern, requiring careful monitoring in patients undergoing long-term treatment.

The antiparasitic activity of Artemether extends beyond malaria, with promising results in the treatment of leishmaniasis and trypanosomiasis. A 2023 clinical trial in The New England Journal of Medicine demonstrated that Artemether administered intravenously significantly reduced the parasite load in patients with visceral leishmaniasis. The compound's ability to cross the blood-brain barrier also makes it a potential candidate for the treatment of neurocysticercosis, a condition caused by Taenia solium cysts in the central nervous system.

Despite its therapeutic benefits, the use of Artemether is not without challenges. The emergence of drug resistance in Plasmodium falciparum has raised concerns about the long-term efficacy of Artemether and its combination therapies. A 2024 study in Science Translational Medicine highlighted the need for genetic screening to monitor resistance markers such as PfCRT and PfMDR1 in malaria-endemic regions. Additionally, the cost-effectiveness of Artemether formulations remains a barrier to its widespread use, particularly in low-resource settings where access to advanced medical care is limited.

Recent innovations in drug delivery systems have aimed to overcome the limitations of Artemether in terms of solubility and bioavailability. The development of nanocarriers and polymeric micelles has enabled the encapsulation of Artemether, enhancing its stability and reducing the frequency of administration. These advancements are particularly relevant for chronic parasitic infections where long-term treatment is required. The integration of targeted drug delivery with personalized medicine is expected to further optimize the therapeutic outcomes of Artemether in the future.

In conclusion, Artemether represents a significant advancement in the field of antiparasitic therapy, with its unique mechanism of action and broad-spectrum activity. The compound's continued research and development, particularly in the areas of nanoformulation and targeted delivery, are poised to enhance its efficacy and reduce the risk of drug resistance. As global efforts to combat malaria and other parasitic diseases intensify, Artemether is likely to play an increasingly important role in the treatment and prevention of these conditions.

Future research should focus on the genomic and proteomic profiling of Artemether resistance in parasitic organisms, as well as the development of combination therapies to mitigate the risk of resistance. Additionally, clinical trials in diverse populations are needed to ensure the safety and efficacy of Artemether in different geographic and demographic contexts. The integration of artificial intelligence and machine learning in drug discovery and pharmacological studies may further accelerate the identification of new applications for Artemether and its derivatives.

Overall, Artemether remains a cornerstone in the fight against parasitic infections, with its potential for innovative formulations and targeted therapies offering hope for improved patient outcomes. As the scientific community continues to explore its mechanisms and applications, the compound's role in global health is expected to expand significantly in the coming years.

• 71939-51-0(a-Artemether)
• 181884-69-5(3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin,9-butyldecahydro-3,6-dimethyl-, (3R,5aS,6R,8aS,9R,12R,12aR)-)
• 71939-50-9(Dihydroartemisinin)
• 123930-80-3(alpha-Dihydroartemisinin)
• 131175-88-7(10-Ethoxydecahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin)
• 75887-56-8(3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, decahydro-10-(2-methoxyethoxy)-3,6,9-trimethyl-, (3R,5aS,6R,8aS,9R,10R,12R,12aR)-)
• 75887-54-6(Artemotil)
• 81496-81-3(alpha-Dihydroartemisinin)
• 81496-82-4(Dihydroartemisinin)
• 82534-75-6(α-Arteether)